New research confirms behavior change driven by Dario digital
platform is sustainable for 12 month period and supports clinical
results for members taking a GLP-1
Additional research demonstrates 31% of Dario members with
Type 2 diabetes achieve results reflecting diabetes
remission
NEW
YORK, June 25, 2024 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market, announced today two new studies
presented this past weekend at the 84th Annual American
Diabetes Association (ADA) Scientific Sessions in Orlando. The first study provides an analysis
of member data for those tracking a GLP-1 medication in Dario's
cardiometabolic solution.
Adopting healthy behaviors while taking a GLP-1 is crucial for
the efficacy of the drug. The sustainability of these behaviors is
proven to be achievable through the innovative technology behind
Dario's cardiometabolic solution and integrated tools for GLP-1
medications. Sustainable behavior change allows users to continue
to realize healthy outcomes after offboarding the drug.
"This new research shows there is tremendous value in giving
people a digital health solution designed for behavior change
alongside GLP-1 medications. We are excited to see this early data
reinforce what we have seen in general member population: our
highly personalized approach to behavior change works," said Yifat
Hershcovitz, PhD., Vice President of Clinical and Scientific
Affairs at Dario.
"Standards of care for cardiometabolic health are evolving
thanks to new GLP-1 medications, but research, including Dario's
newest study, continues to demonstrate the importance of effective
behavior change. These medications require the meaningful and
sustainable change that Dario delivers for our members and our
clients to support full realization of the value of these drugs,"
said Omar Manejwala, M.D., Chief
Medical Officer.
Dario Members Sustain Healthy Behaviors for 12 Months
Alongside While Taking a GLP-1
To understand how Dario can best support members taking a GLP-1,
a retrospective analysis was conducted using data from members
using Dario to manage Type 2 diabetes or prediabetes and taking
either Metformin, a standard medication prescribed for diabetes, or
a GLP-1. Both member groups were tracked for 12 months as they
engaged with Dario's digital chronic condition solution to measure
blood glucose levels and track lifestyle activities such as diet
and exercise. Members also utilized Dario's Medication Cabinet
feature to log Metformin or GLP-1 dataset reminders and report
adherence.
The data showed significant improvement in adopting healthy
behaviors over a 12-month period across both groups as shown by
increased tracking of healthy lifestyle behaviors as shown by
logged meals and physical activity beginning in the first three
months and sustained through the 12-month period.
Dario members using a GLP-1 also experienced additional
improvements to outcomes and behavior change compared to the group
using Metformin:
- Dario members using a GLP-1 experienced a significant reduction
in blood glucose levels in the first 5 months with the changes
sustained through the rest of the year
- Dario members using a GLP-1 demonstrated a significant increase
in the monthly number of weight measurements over 12 months
31% of Dario Members with Type
2 Diabetes Achieve Results Consistent with Diabetes
Remission
Additional research presented by Dario at the ADA conference
examined Dario's ability to help members realize the goal of
diabetes remission for people living with Type 2 diabetes. The ADA
considers remission to be achieve when an individual with Type 2
diabetes sustains normal blood glucose levels of less than 6.5%
HbA1c for three months without the aid of a diabetic
medication.1
This retrospective study analyzed the data of 7,240 individuals
with Type 2 diabetes using Dario to help manage their condition
without the help of insulin for at least six months. The results
demonstrated a significant impact:
- 31% of Dario members experienced blood glucose levels
reflecting the goal of diabetes remission with average blood
glucose readings of less than 140 mg/dL (A1c 6.5%) during a
three-month period
- 70% of Dario members achieved a blood glucose level of
less than 140 mg/dL in their last month of usage maintained it for
three-month period, indicating behavior change and improved
long-term glycemic control
- Lifestyle activities as shown by logged meals and physical
activity moderated the reduction in average blood glucose levels
and high readings ratio.
"Diabetes remission is becoming a more popular goal for people
living with Type 2 diabetes as more clinicians and people realize
the immense benefits to their overall health. This new research
shows that when we empower people with the right solution, we are
giving them the ability to do so much more than control their blood
glucose; they are able to make incredibly hard changes to
accomplish their health goals," said Yifat Hershcovitz, PhD., Vice
President of Clinical and Scientific Affairs at Dario.
"This data is incredibly exciting and confirming of our approach
at Dario. We want every member to find value in Dario, and for
those who seek remission of their Diabetes, we can confidently say
we can help them achieve this goal. This is also extremely
important for our clients as we can demonstrate once again that our
highly personalized approach to engagement delivers best-in-class
outcomes to support chronic condition management goals," said
Omar Manejwala, M.D., Chief Medical
Officer, Dario.
1 Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh
WK, Rothberg AE, Le Roux CW, Rubino F, Schauer P, Taylor R,
Twenefour D. Consensus Report: Definition and Interpretation of
Remission in Type 2 Diabetes. Diabetes Care 2021 Oct 1;44(10):2438–2444. doi:
10.2337/dci21-0034
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it
discusses the benefit of its platform and products, including
in the management of chronic conditions and the potential for
Diabetes remission. Without limiting the generality of the
foregoing, words such as "plan," "project," "potential," "seek,"
"may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat
Parrella
Investor Relations Manager
kat@dariohealth.com
+ 315-378-6922
Media Contact
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo:
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/dario-demonstrates-12-months-of-sustained-healthy-behavior-change-for-members-taking-a-glp-1-302181476.html
SOURCE DarioHealth Corp.
